Thermo Fisher Scientific Inc. $TMO Position Decreased by Castle Rock Wealth Management LLC

Castle Rock Wealth Management LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 69.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,228 shares of the medical research company’s stock after selling 2,826 shares during the quarter. Castle Rock Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $806,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Avity Investment Management Inc. increased its holdings in Thermo Fisher Scientific by 0.5% in the third quarter. Avity Investment Management Inc. now owns 63,581 shares of the medical research company’s stock valued at $42,920,000 after buying an additional 318 shares during the last quarter. Riversedge Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $365,000. Wedmont Private Capital increased its holdings in shares of Thermo Fisher Scientific by 74.4% in the 3rd quarter. Wedmont Private Capital now owns 2,817 shares of the medical research company’s stock valued at $1,837,000 after acquiring an additional 1,202 shares during the last quarter. Athena Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 3.2% during the 3rd quarter. Athena Wealth Management LLC now owns 2,166 shares of the medical research company’s stock worth $1,462,000 after acquiring an additional 68 shares in the last quarter. Finally, Dakota Community Bank & Trust NA boosted its holdings in Thermo Fisher Scientific by 53.8% in the third quarter. Dakota Community Bank & Trust NA now owns 203 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 71 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $720.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. Wells Fargo & Company lowered Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $634.86.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $6.25 during trading on Friday, reaching $658.23. The company had a trading volume of 1,580,669 shares, compared to its average volume of 2,250,091. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $694.33. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock’s fifty day moving average price is $625.73 and its 200 day moving average price is $540.54. The firm has a market capitalization of $243.38 billion, a price-to-earnings ratio of 35.41, a price-to-earnings-growth ratio of 2.77 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.